Epsilon M&A Deal Report - HRA Pharma Rare Diseases
Transaction Multiples for the Valuation of Private Companies
Esteve Pharmaceuticals / HRA Pharma Rare Diseases
No EMAT :
117378
Announced Date :
25/04/2024
Type :
Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Esteve Pharmaceuticals
Target :
HRA Pharma Rare Diseases
Country :
Hauts-De-Seine
Sector of activity :
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Biomedical Research Laboratory
Business Description :
HRA Pharma Rare Diseases is specialized in rare and ultra- rare diseases. > HRA Pharma Rare Diseases has a portfolio of medicines (Metopirone, Lysodren, and Ketoconazole HRA) that address Cushing’s...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
|
|||||
| Current |
Rating :
**
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Biomedical Research Laboratory » = 32
| Date | Acquirer | Target | Country | Multiples | See details |
| 05/06/2024 | Rohto Pharmaceuticals Co | MoNo chem-pharm Produkte (Sigmapharm) | Austria | * | 117090 |
| 27/03/2024 | Private group led by Carvest, Siparex | Capron Podologie | Saône-Et-Loire | * | 116883 |
Source: Epsilon Research / EMAT
